Precision BioSciences Prices $125 Million Offering of Shares and Pre-Funded Warrants
Precision BioSciences (DTIL) priced a $125M offering of 10.2M common shares at $7.75 each and pre-funded warrants for 5.9M shares at $7.75. Net proceeds, excluding warrant exercise, are expected to be $116.5M. Funds will support R&D for PBGENE-HBV and PBGENE-DMD, and general corporate purposes. The offering is set to close on or around November 6, 2026.
How this was made
The 30-second read
Why it matters
The infusion of $116.5 M net proceeds provides runway for its pipeline but introduces dilution, likely prompting a near‑term price decline.
Market read
Primary disclosure of a sizable capital raise for a U.S. biotech, directly affecting DTIL's share price and sector sentiment.
What to watch
Potential strategic partnership or licensing deals stemming from the new cash could boost future revenue.
Background
Precision BioSciences (DTIL) announced a priced equity and warrant offering to fund ongoing gene‑therapy programs and general corporate purposes.
Ticker impact
Precision BioSciences disclosed a $125 million underwritten equity and pre‑funded warrant offering, the first public report of this capital raise.
downward pressure as investors price in dilution and increased share count
Large primary offering at $7.75 per share introduces significant new supply; market typically reacts negatively to such dilutive raises.
Market effects
Biotech sector may see modest sell‑off as investors reassess dilution risk across similar small‑cap gene‑therapy firms.
U.S. biotech market may experience slight downward pressure.
Limited to investors focused on U.S. biotech equities.
Counterpoint
If the raised capital accelerates PBGENE‑HBV and PBGENE‑DMD pipelines, the long‑term upside could outweigh short‑term dilution.
Key entities
- companyPrecision BioSciences
Biotech firm developing gene‑editing therapies.
